An Imatinib-non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization

Ilaria Crespiatico; Elisa Bossi; Filippo Brioschi; Rocco Piazza; Luca Mologni; Carlo Gambacorti-Passerini

doi:10.1002/ccr3.2531

An Imatinib-non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization

Clin Case Rep. 2019 Dec 5;8(1):71-74. doi: 10.1002/ccr3.2531. eCollection 2020 Jan.

Authors

Ilaria Crespiatico¹, Elisa Bossi^{1

2}, Filippo Brioschi^{1

2}, Rocco Piazza^{1

2}, Luca Mologni¹, Carlo Gambacorti-Passerini^{1

2}

Affiliations

¹ Department of Medicine and Surgery University of Milano Bicocca Monza Italy.
² Hematology and Clinical Research Unit San Gerardo Hospital Monza Italy.

Abstract

Leu387Trp mutation, aroused in an imatinib-non-responsive CML patient, was selected by imatinib treatment along with other unknown factors responsible for resistance, and then it was overcome by bosutinib. These results will be useful for treating patients with this rare mutation and will advise against automatically considering a new mutation as the cause of TKI resistance.

Keywords: TKI; chronic myeloid leukemia; genetics; hematology; resistance.

Publication types

Case Reports